MX2022001033A - Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células. - Google Patents

Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células.

Info

Publication number
MX2022001033A
MX2022001033A MX2022001033A MX2022001033A MX2022001033A MX 2022001033 A MX2022001033 A MX 2022001033A MX 2022001033 A MX2022001033 A MX 2022001033A MX 2022001033 A MX2022001033 A MX 2022001033A MX 2022001033 A MX2022001033 A MX 2022001033A
Authority
MX
Mexico
Prior art keywords
aptamers
labeling
cell targeting
immunodiagnostics
immunotherapy
Prior art date
Application number
MX2022001033A
Other languages
English (en)
Inventor
Cecile Bauche
Frederic Mourlane
Renaud Vaillant
Anna Miodek
Original Assignee
Ixaka France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000890 external-priority patent/WO2020021338A2/en
Application filed by Ixaka France filed Critical Ixaka France
Publication of MX2022001033A publication Critical patent/MX2022001033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan secuencias de aptámeros de alta afinidad que reconocen el complejo de proteínas CD3 en las superficies celulares. Los aptámeros se pueden usar como porciones de direccionamiento para suministrar vehículos o como componentes moleculares para inmunoterapia, inmunodiagnóstico o para aislar, purificar o caracterizar células T CD3+ en un sujeto.
MX2022001033A 2019-07-26 2020-07-27 Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células. MX2022001033A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962879413P 2019-07-26 2019-07-26
US201962879401P 2019-07-26 2019-07-26
PCT/IB2019/000890 WO2020021338A2 (en) 2018-07-26 2019-07-26 Aptamer-based car t-cell switch
PCT/IB2020/000635 WO2021019301A2 (en) 2019-07-26 2020-07-27 Anti-cd3 aptamers for use in cell targeting and labeling

Publications (1)

Publication Number Publication Date
MX2022001033A true MX2022001033A (es) 2022-05-24

Family

ID=74229604

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022001032A MX2022001032A (es) 2019-07-26 2020-07-27 Agentes terapeuticos multiespecificos a base en aptameros.
MX2022001033A MX2022001033A (es) 2019-07-26 2020-07-27 Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022001032A MX2022001032A (es) 2019-07-26 2020-07-27 Agentes terapeuticos multiespecificos a base en aptameros.

Country Status (9)

Country Link
US (2) US20220403391A1 (es)
EP (2) EP4004209A2 (es)
JP (2) JP2022542198A (es)
KR (2) KR20220083667A (es)
CN (2) CN114630908A (es)
AU (2) AU2020321673A1 (es)
CA (2) CA3148799A1 (es)
MX (2) MX2022001032A (es)
WO (2) WO2021019297A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111235106B (zh) * 2019-08-30 2022-08-05 武汉大学 一种靶向肿瘤细胞的Aptamer-CD3+T细胞及其构建方法与应用
CN114990122A (zh) * 2022-05-18 2022-09-02 清华大学 共价抑制剂的体外筛选方法及其应用
CN115786349B (zh) * 2022-08-16 2024-02-09 湖南大学 一种用于外周血中杀伤性t淋巴细胞无痕分选的核酸适体、互补序列及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
BRPI0514984A (pt) * 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US11634704B2 (en) * 2015-04-13 2023-04-25 Research Foundation Of The City University Of New York Ligand-guided-selection method for screening antigen-specific ligands
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
SI3411404T1 (sl) * 2016-02-03 2023-01-31 Amgen Research (Munich) Gmbh Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico
EP3416690A4 (en) * 2016-02-19 2020-02-19 City of Hope SPECIFIC APTAMER
CN107129988A (zh) * 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
US20210292760A1 (en) * 2018-07-26 2021-09-23 Aratinga.Bio Tnp Aptamer-Based CAR T-Cell Switch

Also Published As

Publication number Publication date
JP2022542198A (ja) 2022-09-29
AU2020321673A1 (en) 2022-03-17
WO2021019297A1 (en) 2021-02-04
WO2021019301A3 (en) 2021-03-11
WO2021019301A2 (en) 2021-02-04
MX2022001032A (es) 2022-05-24
EP4004208A1 (en) 2022-06-01
CN114630908A (zh) 2022-06-14
CN114630907A (zh) 2022-06-14
CA3148792A1 (en) 2021-02-04
JP2022544337A (ja) 2022-10-17
US20220403391A1 (en) 2022-12-22
US20220251562A1 (en) 2022-08-11
AU2020320420A1 (en) 2022-03-17
EP4004209A2 (en) 2022-06-01
CA3148799A1 (en) 2021-02-04
KR20220084272A (ko) 2022-06-21
KR20220083667A (ko) 2022-06-20

Similar Documents

Publication Publication Date Title
MX2022001033A (es) Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células.
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
MX2023001403A (es) Neoantigenos y metodos de su uso.
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
WO2019008123A3 (en) CELLS, VERTEBRATES, POPULATIONS AND METHODS
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
MX2017009181A (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
GB2544014A (en) Systems and methods for implementing hybrid dynamic wallet tokens
MX2019011907A (es) Nuevas moleculas de union a antigeno biespecificas capaces de unirse especificamente a cd40 y a fap.
MX2018010415A (es) Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
NZ616761A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
EP3447072A3 (en) Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
MX340498B (es) Polipeptido heterodimerizado.
SG196839A1 (en) Antibodies against fcrn and use thereof
NZ623086A (en) Therapeutic peptides
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX2010002968A (es) Proteinas de enlace de antigeno gm-csf humano.
EP2534257A4 (en) METHOD OF IDENTIFYING AND ISOLATING CELLS FOR THE EXPRESSION OF POLYPEPTIDES
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
MX2018007781A (es) Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
MX2011004483A (es) Leucolectinas y sus usos.
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
NZ610091A (en) Antibodies
MX2021008216A (es) Anticuerpos anti-tigit.